

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 August 2020 (27.08.2020)



(10) International Publication Number
WO 2020/172598 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) A61P 37/02 (2006.01)
(21) International Application Number:
PCT/US2020/019321

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:
21 February 2020 (21.02.2020)

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(25) Filing Language: English
(26) Publication Language: English

(30) Priority Data:
62/808,713 21 February 2019 (21.02.2019) US
62/957,045 03 January 2020 (03.01.2020) US

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **ELSTAR THERAPEUTICS, INC.** [US/US];
840 Memorial Drive, 4th Floor, Cambridge, MA 02139
(US).

(72) Inventors: **LOEW, Andreas**; 840 Memorial Drive, 4th
Floor, Cambridge, MA 02139 (US). **TAN, Seng-Lai**; 840
Memorial Drive, 4th Floor, Cambridge, MA 02139 (US).
HSU, Jonathan; 840 Memorial Drive, 4th Floor, Cam-
bridge, MA 02139 (US). **VASH, Brian, Edward**; 840
Memorial Drive, 4th Floor, Cambridge, MA 02139 (US).
MAIOCCO, Stephanie, J.; 840 Memorial Drive, 4th
Floor, Cambridge, MA 02139 (US). **MALHOTRA, Nid-
hi**; 840 Memorial Drive, 4th Floor, Cambridge, MA 02139
(US). **KATRAGADDA, Madan**; 840 Memorial Drive, 4th
Floor, Cambridge, MA 02139 (US).

(74) Agent: **COLLAZO, Diana, M.** et al.; Lando & Anastasi,
LLP, 60 State Street, 23rd Floor, Boston, MA 02109 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: MULTIFUNCTIONAL MOLECULES THAT BIND TO T CELLS AND USES THEREOF TO TREAT AUTOIMMUNE DISORDERS

(57) Abstract: Multifunctional molecules that include i) an antigen binding domain that binds to a TCR variable beta chain (TCRBV) antigen; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule or cytokine inhibitor molecule; and/or (iv) a death receptor signal enhancer. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating autoimmune diseases using the aforesaid molecules.

WO 2020/172598 A1